Tercica

Tercica is a biopharmaceutical company that specializes in the development and commercialization of endocrine-related therapeutic products. The company is best known for its product Increlex, which is used in the treatment of growth failure in children with severe primary IGF-1 deficiency or with Growth Hormone (GH) gene deletion who have developed neutralizing antibodies to GH.

History

Tercica was founded in 2002 and is headquartered in Brisbane, California. The company was acquired by Ipsen in 2008, a global specialty-driven pharmaceutical group.

Products

Tercica's main product is Increlex. Increlex is a recombinant form of human IGF-1, which is an important mediator of the effects of growth hormone. It is used to treat children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone.

Clinical Trials

Tercica has conducted several clinical trials to evaluate the safety and efficacy of Increlex. These trials have demonstrated that Increlex is effective in increasing linear growth rate and improving height in children with severe primary IGF-1 deficiency or with growth hormone gene deletion who have developed neutralizing antibodies to growth hormone.

Side Effects

Like all medications, Increlex can cause side effects. The most common side effects include hypoglycemia, lipohypertrophy, tonsillar hypertrophy, and snoring. Less common side effects include intracranial hypertension, otitis media, and scoliosis.

See Also

• Ipsen
• Endocrinology
• Growth hormone
• IGF-1

References

This article is a stub related to pharmacology. You can help WikiMD by expanding it!